Evidence map›Paper›PMID 40524964›Full record

ArticleCase reports in oncology

Heavily Pretreated Refractory Diffuse Large B-Cell Lymphoma Successfully Treated with Epcoritamab: Case Report.

Jeremy Rosiecki, Natalie Wallace, Katelyn Kammers, Ann-Chee Cheng, Talia Wyckoff, Steven Liu

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jeremy RosieckiAlaska Oncology and Hematology, Alaska Regional Hospital, Anchorage, AK, USA.
Natalie WallaceAlaska Oncology and Hematology, Alaska Regional Hospital, Anchorage, AK, USA.
Katelyn KammersProvidence Alaska Medical Center, Anchorage, AK, USA.
Ann-Chee ChengProvidence Alaska Medical Center, Anchorage, AK, USA.
Talia WyckoffAlaska Oncology and Hematology, Alaska Regional Hospital, Anchorage, AK, USA.
Steven LiuAlaska Oncology and Hematology, Alaska Regional Hospital, Anchorage, AK, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) poses considerable treatment challenges, with disheartening odds of long-term survival. Numerous strategies exist, including non-cross-resistant combination chemoimmunotherapy regimens, autologous stem cell transplantation, and chimeric antigen receptor (CAR) T-cell therapy, but some patients are not appropriate candidates or cannot sustain response to treatment. Epcoritamab, a bispecific CD20-directed CD3 T-cell engager, has been given accelerated approval by the US Food and Drug Administration for relapsed or refractory DLBCL. Case Presentation: We present the case of a 61-year-old male diagnosed with stage 4 "double-hit" DLBCL with Conclusion: T-cell engager therapies, such as epcoritamab, can play a role in managing patients with refractory DLBCL, including those refractory to CAR T-cell therapy.

Indexed as

Bispecific T-cell engagerCase reportChimeric antigen receptor T-cell therapyNon-Hodgkin lymphoma

Identifiers

PMID40524964
PMCPMC12169811

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.